Patients with cutaneous squamous cell carcinoma (cSCC) treated with immune checkpoint inhibitors (ICIs) show a delayed response after confirmed progression (DR), according to a Victorian report. Researchers from the Peter MacCallum Cancer Centre have described three cases with unconfirmed disease progression after treatment of lesions with either cemiplimab or pembrolizumab. Signs included increased size of ...
Patients with advanced NMSC show nuanced responses to immunotherapy
By Mardi Chapman
17 May 2021